Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update - Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complet

Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete

response rate, and favorable safety profile -

Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company's

first U.S. pivotal study -

Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control

and favorable safety, the first oral presentation of Alpha DaRT pancreatic data at a premier international gastroenterology

Abstracts accepted for presentation at the 2026 ASCO Annual Meeting and at the AHNS 12th International Conference on Head and Neck Cancer,

reflecting growing scientific recognition across multiple solid tumor indications -

FDA approval of an IDE supplement to expand the IMPACT pancreatic cancer trial to patients receiving gemcitabine with Abraxane

(nab-paclitaxel) and recruit additional patients -

First patient successfully treated for pancreatic cancer in Europe at CHU Grenoble Alpes under the multicenter ACAPELLA trial in France,

and first patient successfully treated in Italy at the University of Verona's Pancreas Institute -

Cash, cash equivalents, short-term deposits and restricted deposits balance of $80.2 million provides runway for continued clinical advancement

and commercial preparation -

May 18, 2026 - Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer

of the innovative alpha-radiation cancer therapy Alpha DaRT , reported first quarter 2026 financial results and provided

first quarter of 2026 has been a truly defining period for Alpha Tau, reflecting the convergence of two powerful dynamics that have been

years in the making: the maturation of clinical data from our most advanced programs, and the global initiation of novel trials addressing

some of the most pressing unmet needs in oncology," said Alpha Tau CEO Uzi Sofer. "The groundbreaking interim

results from our U.S. REGAIN trial in recurrent glioblastoma, with 100% local disease control and a 67% complete response rate as of

May 3, represent powerful potential clinical benefit in patients facing a devastating disease with virtually no curative options. Our

pancreatic cancer program has also continued to build compelling data, first with positive new results from our Montreal study presented

at the ASCO Gastrointestinal Cancers Symposium, then with the oral presentation of pooled pancreatic data at Digestive Disease Week 2026,

and most recently with the expansion of our IMPACT pancreatic trial to include patients receiving gemcitabine with Abraxane

the same time, we have continued to make significant strides toward commercialization on both sides of the Pacific, following

our receipt of PMDA marketing approval in Japan for Alpha DaRT in unresectable locally advanced or locally recurrent head and neck cancer,"

continued Mr. Sofer. "In Japan, we are working closely with our selected leading clinical centers to advance the post-market surveillance

study that supports our marketing approval. In the United States, we are advancing steadily along our path to potential FDA approval,

with the recent completion of patient enrollment with 88 patients in our pivotal ReSTART trial, our very first U.S. pivotal study to

reach this milestone."

"Taken together, this quarter is a true

culmination of years of disciplined execution across each of our strategic priorities. With a strong balance sheet with $80.2 million

of liquidity to support our continued momentum, we aim to translate this remarkable progress into meaningful impact for patients."

Corporate Highlights:

Upcoming Milestone Targets:

Results for the Three Months Ended March 31, 2026

and Development expenses for the three months ended March 31, 2026 were $11.0 million, compared to $7.2 million for the same period in

2025, primarily due to increased clinical trial activity, increased employee compensation and benefits, including share-based compensation,

increased raw material purchases, and milestone payments associated with our receipt of PMDA marketing authorization in Japan.

expenses for the three months ended March 31, 2026 were $0.2 million, compared to $0.5 million for the same period in 2025, primarily

due to decreased employee compensation and benefits and marketing conference activities.

and Administrative expenses for the three months ended March 31, 2026 were $2.1 million, compared to $1.7 million for the same period

in 2025, primarily due to increased employee compensation and benefits, including share-based compensation, and higher professional fees.

expenses, net, for the three months ended March 31, 2026 were $9.6 million, compared to financial income, net, of $0.7 million for the

same period in 2025, primarily due to the remeasurement of warrants liability.

the three months ended March 31, 2026, the Company had a net loss of $22.9 million, or $0.26 per share, compared to a net loss of $8.7

million, or $0.12 per share, for the three months ended March 31, 2025.

of March 31, 2026, the Company had cash and cash equivalents, short-term deposits and restricted deposits of $80.2 million, compared

to $76.9 million at December 31, 2025.

DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation

of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released

from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting

atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Alpha Tau Medical Ltd.

in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization

of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari

from Tel Aviv University.

press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of

1995. When used herein, words including "anticipate," "will," "plan," "may," "continue,"

and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to

expectations, milestone targets, beliefs, plans, including with respect to clinical trials and planned treatments, regulatory approvals

and expected responses, studies, patient recruitment, projections, objectives, performance, our ability to commercialize, applications

with regulatory bodies or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there

is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations,

and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking

statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory

approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history;

(iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise

capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence

on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical

studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict

future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused

by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement

lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's

listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important

factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on

March 9, 2026 , and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other

important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this

press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While

Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any

obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon

as representing Alpha Tau's views as of any date subsequent to the date of this press release.

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS

in thousands (except share and per share data)

CONSOLIDATED STATEMENTS OF OPERATIONS

in thousands (except share and per share data)